WallStreetZenWallStreetZen

NASDAQ: DNLI
Denali Therapeutics Inc Stock Ownership - Who owns Denali Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Denali Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Ryan J. WattsPresident and CEO2026-01-0635,198$16.50
$580.77kSell
Alexander O. SchuthCOFO and Secretary2026-01-0617,218$16.50
$284.10kSell
Carole HoChief Medical Officer2025-08-13806$14.64
$11.80kSell
Alexander O. SchuthCOFO and Secretary2025-08-122,937$13.58
$39.88kSell
Carole HoChief Medical Officer2025-08-122,937$13.58
$39.88kSell
Carole HoChief Medical Officer2025-08-0544,655$0.68
$30.37kBuy
Ryan J. WattsPresident and CEO2025-07-09455,282$0.68
$309.59kBuy
Ryan J. WattsPresident and CEO2025-07-0940,000$5.28
$211.20kBuy
Ryan J. WattsPresident and CEO2025-07-09495,282$15.00
$7.43MSell

1 of 1

DNLI insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when DNLI insiders and whales buy or sell their stock.

DNLI Shareholders

What type of owners hold Denali Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Robert Nelsen13.07%20,749,930$375.78MInsider
Biogen Inc8.39%13,310,243$241.05MInsider
Blackrock Inc8.21%13,034,434$236.05MInstitution
Baillie Gifford Co7.60%12,066,479$218.52MInstitution
Arch Venture Fund VIII LP6.72%10,668,749$193.21MInsider
Douglas K. Bratton6.35%10,084,938$182.64MInsider
Fmr LLC6.16%9,779,988$177.12MInsider
Flagship Ventures Fund V LP5.62%8,918,749$161.52MInsider
T Rowe Price Investment Management Inc5.37%8,519,192$154.28MInstitution
Temasek Holdings Private Ltd4.42%7,012,974$127.00MInstitution

1 of 3

DNLI vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
DNLI62.35%37.65%Net Selling
RCUS67.92%32.08%Net SellingNet Selling
TNGX68.40%31.60%Net SellingNet Selling
DYN84.14%15.86%Net SellingNet Selling
ALMS77.20%22.80%Net Buying
View Top Biotech Stocks

Denali Therapeutics Stock Ownership FAQ

Who owns Denali Therapeutics?

Denali Therapeutics (NASDAQ: DNLI) is owned by 92.76% institutional shareholders, 56.00% Denali Therapeutics insiders, and 0.00% retail investors. Robert Nelsen is the largest individual Denali Therapeutics shareholder, owning 20.75M shares representing 13.07% of the company. Robert Nelsen's Denali Therapeutics shares are currently valued at $390.72M.

If you're new to stock investing, here's how to buy Denali Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.